<0> BioTime, Inc.Judith Segall, 510-521-3390 ext. 301orInvestor Contact:EVC Group, Inc.Gregory Gin, 862-236-0673James Dawson, 646-445-4800Doug Sherk, 415-652-9100 </0> , Inc. (NYSE MKT: BTX) announced ...
BioTime completes expected acquisition of Asterias. Shares move 7% higher as BioTime broadens pipeline. Top management and a promising clinical program make BTX attractive. Shares of BioTime, Inc.
BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results